Skip to content

Effect of aromatherapy message and foot reflexology on fatigue in patients undergoing dialysis

Comparison of aromatherapy message and foot reflexology on outcomes in patients undergoing dialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201612067529N11
Enrollment
105
Registered
2016-12-16
Start date
2016-10-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patient. Chronic kidney disease, stage 5

Interventions

Intervention 1: reflexology intervention group for 20 minutes (10 minutes for each leg) 3 times a week, for 12 weeks will do. Intervention 2: In aromatherapy message intervention group
all subjects are undergone skin testing before massage with aromatic oil to ensure the absence of sensitivity
in case of redness, itching, swelling, and a positive test, the patient was excluded. The subjects in this group were massaged with 5 ml combination of lavender essence which is diluted with 15 ml swe
Treatment - Other
reflexology intervention group for 20 minutes (10 minutes for each leg) 3 times a week, for 12 weeks will do.
In aromatherapy message intervention group
In the placebo group in other parts of the foot massage points will be done and they will receive routine care during dialysis.

Sponsors

Shahed University Vice Chancellor For Research
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: female patients with chronic renal failure; the desire to participate in the study; age at least 18 years old and at least 6 months of dialysis; being on the list and do the weekly dialysis three times a week; having full awareness; listening and speaking ability acceptable to answer questions; restless leg syndrome is confirmed by GP; develop a degree of fatigue on the Fatigue Severity Scale; lack of fever and bleeding and thrombosis, infection; ulcers numbness or paralysis of the limbs; no peripheral neuropathy or vascular problems in legs; menopause and drug addiction Exclusion criteria: patient dissatisfaction to continue participation in the study; patients died during the study; transplantation during the study; condition of hemodynamic is unstable; according to the doctor if the patient is in need of special treatment the patient is excluded .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity Restless leg syndrome. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Restless leg syndrome rating scale.;Quality of sleep. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Pittsburgh Sleep Quality Index.;Fatigue. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Piper Fatigue Scale.;Blood pressure. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Checklist.;Respiratory rate. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Checklist.;Pulse rate. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Checklist.;Mean blood pressure. Timepoint: Before the intervention in first session, eight weeks after the intervention, twelve weeks after the intervention. Method of measurement: Checklist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nahid Rejeh

Shahed University

nrejeh@yahoo.com+98 21 5121 3071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026